Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
September 20, 2024 08:43 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse...
Novo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
September 19, 2024 15:10 ET
|
Novo Nordisk A/S
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function Wegovy® (semaglutide 2.4 mg) is the first...
Novo Nordisk A/S - share repurchase programme
September 16, 2024 09:15 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 16 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
September 09, 2024 10:10 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S - share repurchase programme
September 09, 2024 09:55 ET
|
Novo Nordisk A/S
Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 9 September 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
August 30, 2024 04:39 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 30 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk A/S - share repurchase programme
August 26, 2024 09:44 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 26 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
August 20, 2024 15:35 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk A/S - share repurchase programme
August 19, 2024 08:48 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 19 August 2024 – On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
August 14, 2024 07:40 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 14 August 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...